Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Active Psoriatic Arthritis Clear all

Conditions: Juvenile Psoriatic Arthritis
Interventions: Adalimumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: CNTO 148 (Golimumab), Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more

Conditions: Psoriatic Arthritis
Interventions: Apremilast 30 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Palm Desert, California • Brandon, Florida + 20 more

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more

Conditions: Psoriatic Arthritis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 81
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more

Conditions: Psoriatic Arthritis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 59
States / cities: Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Ustekinumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Tucson, Arizona • Fountain Valley, California • La Mesa, California + 13 more

Conditions: Psoriatic Arthritis
Interventions: AbGn-168H; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Psoriatic Arthritis (PsA)
Interventions: GLP-1 agonists, Nutrition Counseling; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Golimumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Searcy, Arkansas • Avon Park, Florida + 16 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 31
States / cities: Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more

Conditions: Psoriatic Arthritis
Interventions: adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Psoriatic Arthritis
Interventions: Open label H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Psoriatic Arthritis
Interventions: NDI-034858, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Palm Desert, California • Upland, California • Hollywood, Florida + 19 more

Conditions: Psoriatic Arthritis
Interventions: Lutikizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 13 more

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 30
States / cities: Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more

Conditions: Arthritis, Psoriatic
Interventions: placebo, ustekinumab 45 mg, ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more

Conditions: Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions: e-Device; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more

Search by objective public record fields.

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis Study of Izokibep

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)